Skip to main content

Table 5 Multivariate analysis of overall survival

From: Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer

  p-value Hazard Ratio 95%-Confidence Interval
RAS p21
Elevated vs. non elevated
0.003 2.927 1.43–5.99
CTC counts
≥5 vs. < 5 CTCs / 7.5 ml blood
< 0.001 3.775 2.01–7.10
Therapy line
> 1st line vs. 1st line
0.002 2.817 1.48–5.37
Grading
G3 vs. G1/2
0.026 1.380 1.04–1.83
Serum HER2
Elevated vs. non elevated
0.156 1.564 0.84–2.90
Menopausal status
Post- vs. Premenopausal
0.298 0.732 0.41–1.32
ER status
Positive vs. Negative
0.067 0.478 0.22–1.05
PR status
Positive vs. Negative
0.486 1.297 0.62–2.70
HER2 status
Positive vs. Negative
0.121 0.623 0.34–1.13
Number of metastatic sites
Multiple vs. Single site
0.521 1.262 0.62–2.57
Metastatic spread
Visceral (+/−) vs. bone only
0.567 1.566 0.33–7.54
CAIX
Elevated vs. non elevated
0.300 1.381 0.75–2.54
TIMP1
Elevated vs. non elevated
0.066 1.741 0.96–3.15